| Nab-paclitaxel | advanced breast cancer (metastatic), in all type of patients | vs docetaxel | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Gradishar, 2009 | weekly and every 3 week (q3w) nab-paclitaxel | docetaxel | first-line treatment in patients with MBC |
| |
| Nab-paclitaxel | | vs gencitabine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Roy, 2008 | weekly nab (nanoparticle albumin-bound)-paclitaxel in combination with gemcitabine | | patients with previously untreated metastatic breast cancer |
| |
| Docetaxel | advanced breast cancer (metastatic), in all type of patients | vs doxorubicin + cyclophosphamide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| JCOG, 2005 | | | first-line chemotherapy in metastatic breast cancer |
| |
| Docetaxel | | vs epirubicin, cyclophosphamide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Blohmer, 2010 | ED (epirubicin 75 mg/m(2) and docetaxel 75 mg/m(2)) | EC (epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2)). | first-line therapy for women with metastatic breast cancer |
| |
| Docetaxel | | vs fluorouracil, doxorubicin, cyclophosphamide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Bontenbal, 2005 | AT (doxorubicin 50 mg/m(2) and docetaxel 75 mg/m2) | FAC (fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2); | first-line chemotherapy in patients with metastatic breast cancer: |
| |
| Docetaxel | | vs fluorouracil, epirubicin, cyclophosphamide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Bonneterre, 2004 | docetaxel 75 mg m(-2) plus epirubicin 75 mg m(-2) | 5-fluorouracil 500 mg m(-2) plus epirubicin 75 mg m(-2) and cyclophosphamide 500 mg m(-2) intravenously once every 3 weeks for up to eight cycles | |
| |
| Docetaxel | | vs fluorouracil, vinorelbine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| TXT Group, 2002 | docetaxel (100 mg m(-2)) every 3 weeks | 5-fluorouracil+vinorelbine: 5-fluorouracil (750 mg m(-2) per day continuous infusion) D1-5 plus vinorelbine (25 mg m(-2)) D1 and D5 of each 3-week cycle | patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy |
| |
| Docetaxel | | vs mitomycin, vinblastine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| 304 Study Group, 1999 | docetaxel 100 mg/m2 intravenously (i.v.) every 3 weeks | mitomycin 12 mg/m2 i.v. every 6 weeks plus vinblastine 6 mg/m2 i.v. every 3 weeks | patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy |
| |
| Docetaxel | | vs sequential methotrexate and 5-fluorouracil | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Sjostrom, 1999 | Docetaxel at a dose of 100 mg/m2 every 3 weeks | sequential methotrexate and 5-fluorouracil | patients with advanced breast cancer who had failed previous anthracycline treatment |
| |
| Docetaxel | | vs vinorelbine, trastuzumab | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| HERNATA, 2011 | docetaxel 100 mg/m(2) day 1 | vinorelbine 30 to 35 mg/m(2) on days 1 and 8 | first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer |
| |
| Docetaxel | | vs Every three weeks Docetaxel | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Rivera , 2008 | Weekly Docetaxel 35–40 mg/m2 | Every three weeks Docetaxel 75–100 mg/m2 | Metastatic patients with metastatic breast cancer | | Tabernero , 2004 | Weekly Docetaxel 40 mg/m2 | Every three weeks Docetaxel 100 mg/m2 | Metastatic | | Sedky , 2002 | Weekly Docetaxel 35 mg/m2 | Every three weeks Docetaxel 100 mg/m2 | Metastatic | | Willemse , 2007 | Weekly Docetaxel 36 mg/m2 | Every three weeks Docetaxel 100 mg/m2 | Metastatic |
| |
| Docetaxel | | vs | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| TAX 317 (Shepherd) 100mg/m2, 2000 | docetaxel 100 mg/m(2) | best supportive care | Patients with performance statuses of 0 to 2 and stage IIIB/IV non-small-cell lung cancer | | TAX 320 100mg/m2, 2000 | docetaxel 100 mg/m(2) (D100) or 75 mg/m(2) (D75) | control regimen of vinorelbine or ifosfamide | patients with advanced non-small-cell lung cancer who had previously failed platinum-containing chemotherapy |
| |
| Docetaxel | | vs 3-weekly docetaxel | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| DISTAl 01 (Gridelli) , 2004 | | | patients with advanced NSCLC patients, < or =75 years, ECOG PS < or =2 | | Camps , | docetaxel 36 mg/m(2) given weekly (1W arm) for 6 weeks followed by 2 weeks of rest | docetaxel 75 mg/m(2) administered every 3 weeks | | | Schuette , | | | | | Gervais , | | | | | Lai , | | | | | Chen , | | | |
| |
| Docetaxel | | vs m2docetaxel 36 mg/ | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Esteban, 2003 | paclitaxel 80 mg/m2 as a 1 h weekly infusion for 6 weeks
followed by a 2-week rest | docetaxel 36 mg/m2 as a 1 h weekly infusion for 6 weeks
followed by a 2-week rest. | patients with NSCLC previously treated with platinum-based
chemotherapy |
| |
| Paclitaxel | advanced breast cancer (metastatic), in all type of patients | vs cisplatin, etoposide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| TOG, 2005 | | | |
| |
| Paclitaxel | | vs CMFP | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| ANZ TITG, 1999 | paclitaxel 200 mg/m(2) intravenously (IV) over 3 hours for eight cycles (24 weeks) | standard cyclophosphamide 100 mg/m(2)/d orally on days 1 to 14, methotrexate 40 mg/m(2) IV on days 1 and 8, fluorouracil 600 mg/m(2) IV on days 1 and 8, and prednisone 40 mg/m(2)/d orally on days 1 to 14 (CMFP) for six cycles (24 weeks) with epirubicin re | front-line therapy in untreated metastatic breast cancer |
| |
| Paclitaxel | | vs epirubicin, cyclophosphamide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| UKCCCR AB01, 1997 | EP (epirubicin 75 mg/m2 and paclitaxel 200 mg/m2) | EC (epirubicin 75 mg/m2 and cyclophosphamide 600 mg/m2) administered intravenously every 3 weeks for a maximum of six cycles | first-line chemotherapy for metastatic breast cancer |
| |
| Paclitaxel | | vs fluorouracil, doxorubicin, cyclophosphamide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Jassem, 2001 | | | first-line therapy for women with metastatic breast cancer |
| |
| Paclitaxel | | vs fluorouracil, epirubicin, cyclophosphamide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| CECOG BM1, 2005 | gemcitabine (1,000 mg/m(2), days 1 and 4), epirubicin (90 mg/m(2), day 1), and paclitaxel (175 mg/m(2), day 1) | FU (500 mg/m(2), day 1), epirubicin (90 mg/m(2), day 1), and cyclophosphamide (500 mg/m(2), day 1) | first-line chemotherapy in metastatic breast cancer |
| |
| Paclitaxel | | vs Every three weeks Docetaxel | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Gradishar , 2009 | Weekly Nab-paclitaxel 100 mg/m2 | Every three weeks Docetaxel 100 mg/m2 | Metastatic | | Fountzilas , 2008 | Weekly Paclitaxel 80 mg/m2 | Every three weeks Gemc. Docetaxel 75 mg/m2 | Metastatic |
| |
| Paclitaxel | | vs Every three weeks Paclitaxel | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| CLGB 9840 (Seidman), 2008 | Weekly Paclitaxel 80 mg/m2 | Every three weeks Paclitaxel 175 mg/m2 | Metastatic | | Frasci , 2006 | Weekly Epi CDDP Paclitaxel 120 mg/m2 | Every three weeks Epi Paclitaxel 175 mg/m2 | LABC | | Frasci , 2005 | Weekly Epi CDDP Paclitaxel 120 mg/m2 | Every three weeks Epi Paclitaxel 175 mg/m2 | Metastatic | | Sikov , 2002 | Weekly Paclitaxel 150 mg/m2 | Split D1,8 every three weeks Paclitaxel 175 mg/m2 | Metastatic | | Khoo , 2006 | split-dose paclitaxel or docetaxel in combination with gemcitabine | Every three weeks Gemc. Paclitaxel 175 mg/m2 | Metastatic patients with metastatic breast cancer (MBC) who had previously received anthracyclines |
| |
| Paclitaxel | | vs capecitabine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Talbot, 2002 | i.v. paclitaxel (175 mg m(-2), | 3-week cycles of intermittent oral capecitabine (1255 mg m(-2) twice daily, days 1-14, | |
| |
| Paclitaxel | | vs doxorubicin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| ECOG E1193 (B), 2003 | paclitaxel (175 mg/m(2)/24 h), | doxorubicin (60 mg/m(2)), | patients with metastatic breast cancer | | EORTC 10923, 2000 | | | first-line therapy of advanced breast cancer |
| |
| Paclitaxel | | vs mitomycin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Dieras, 1995 | paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks | mitomycin 12 mg/m2 given as an intravenous infusion every 6 weeks | advanced breast cancer |
| |
